Clinical features, management, and therapy of plasma cell neoplasms

What pathologists need to know

Giampaolo Talamo, Cerisse Harcourt, Maurizio Zangari

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Plasma cell neoplasms are characterized by the proliferation of monoclonal plasma cells and include a spectrum of disorders with different clinical manifestations. Multiple myeloma (MM) is the second most common hematological malignancy and recent studies have indicated that almost all cases of MM are preceded by a precursor state of monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). The main clinical manifestations of MM are summarized by the CRAB symptoms: hypercalcemia, renal insufficiency, anemia, and bone lesions. Survival of multiple myeloma patients has significantly improved in the last two decades. The clinical benefit has occurred mainly in the younger population with the introduction of high-dose chemotherapy and autologous stem cell transplantation (ASCT) and with the use of novel agents at the time of relapse. The use of novel agents in the elderly population has also resulted in a significant benefit with respect to outcome. Despite the use of these new agents, and the improvement of the median survival from 3 to 6 years in the last 20 years, MM is generally considered an incurable disease and relapse occurs in virtually all patients. Cytogenetic analysis and molecular biology studies indicate that MM is a heterogeneous disease. The non-satisfactory cure rate has been conditioned by intraclonal heterogeneity with branching evolutionary patterns.

Original languageEnglish (US)
Title of host publicationPlasma Cell Neoplasms
Subtitle of host publicationPathogenesis, Diagnosis and Laboratory Evaluation
PublisherSpringer International Publishing
Pages9-34
Number of pages26
ISBN (Electronic)9783319423708
ISBN (Print)9783319423685
DOIs
StatePublished - Jan 1 2016

Fingerprint

Plasma Cell Neoplasms
Multiple Myeloma
Therapeutics
Monoclonal Gammopathy of Undetermined Significance
Recurrence
Survival
Cytogenetic Analysis
Hypercalcemia
Stem Cell Transplantation
Hematologic Neoplasms
Plasma Cells
Population
Renal Insufficiency
Pathologists
Anemia
Molecular Biology
Bone and Bones
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Talamo, G., Harcourt, C., & Zangari, M. (2016). Clinical features, management, and therapy of plasma cell neoplasms: What pathologists need to know. In Plasma Cell Neoplasms: Pathogenesis, Diagnosis and Laboratory Evaluation (pp. 9-34). Springer International Publishing. https://doi.org/10.1007/978-3-319-42370-8_2
Talamo, Giampaolo ; Harcourt, Cerisse ; Zangari, Maurizio. / Clinical features, management, and therapy of plasma cell neoplasms : What pathologists need to know. Plasma Cell Neoplasms: Pathogenesis, Diagnosis and Laboratory Evaluation. Springer International Publishing, 2016. pp. 9-34
@inbook{1bdb8b52f66f47989704f417ba933cce,
title = "Clinical features, management, and therapy of plasma cell neoplasms: What pathologists need to know",
abstract = "Plasma cell neoplasms are characterized by the proliferation of monoclonal plasma cells and include a spectrum of disorders with different clinical manifestations. Multiple myeloma (MM) is the second most common hematological malignancy and recent studies have indicated that almost all cases of MM are preceded by a precursor state of monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). The main clinical manifestations of MM are summarized by the CRAB symptoms: hypercalcemia, renal insufficiency, anemia, and bone lesions. Survival of multiple myeloma patients has significantly improved in the last two decades. The clinical benefit has occurred mainly in the younger population with the introduction of high-dose chemotherapy and autologous stem cell transplantation (ASCT) and with the use of novel agents at the time of relapse. The use of novel agents in the elderly population has also resulted in a significant benefit with respect to outcome. Despite the use of these new agents, and the improvement of the median survival from 3 to 6 years in the last 20 years, MM is generally considered an incurable disease and relapse occurs in virtually all patients. Cytogenetic analysis and molecular biology studies indicate that MM is a heterogeneous disease. The non-satisfactory cure rate has been conditioned by intraclonal heterogeneity with branching evolutionary patterns.",
author = "Giampaolo Talamo and Cerisse Harcourt and Maurizio Zangari",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-42370-8_2",
language = "English (US)",
isbn = "9783319423685",
pages = "9--34",
booktitle = "Plasma Cell Neoplasms",
publisher = "Springer International Publishing",

}

Talamo, G, Harcourt, C & Zangari, M 2016, Clinical features, management, and therapy of plasma cell neoplasms: What pathologists need to know. in Plasma Cell Neoplasms: Pathogenesis, Diagnosis and Laboratory Evaluation. Springer International Publishing, pp. 9-34. https://doi.org/10.1007/978-3-319-42370-8_2

Clinical features, management, and therapy of plasma cell neoplasms : What pathologists need to know. / Talamo, Giampaolo; Harcourt, Cerisse; Zangari, Maurizio.

Plasma Cell Neoplasms: Pathogenesis, Diagnosis and Laboratory Evaluation. Springer International Publishing, 2016. p. 9-34.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Clinical features, management, and therapy of plasma cell neoplasms

T2 - What pathologists need to know

AU - Talamo, Giampaolo

AU - Harcourt, Cerisse

AU - Zangari, Maurizio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Plasma cell neoplasms are characterized by the proliferation of monoclonal plasma cells and include a spectrum of disorders with different clinical manifestations. Multiple myeloma (MM) is the second most common hematological malignancy and recent studies have indicated that almost all cases of MM are preceded by a precursor state of monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). The main clinical manifestations of MM are summarized by the CRAB symptoms: hypercalcemia, renal insufficiency, anemia, and bone lesions. Survival of multiple myeloma patients has significantly improved in the last two decades. The clinical benefit has occurred mainly in the younger population with the introduction of high-dose chemotherapy and autologous stem cell transplantation (ASCT) and with the use of novel agents at the time of relapse. The use of novel agents in the elderly population has also resulted in a significant benefit with respect to outcome. Despite the use of these new agents, and the improvement of the median survival from 3 to 6 years in the last 20 years, MM is generally considered an incurable disease and relapse occurs in virtually all patients. Cytogenetic analysis and molecular biology studies indicate that MM is a heterogeneous disease. The non-satisfactory cure rate has been conditioned by intraclonal heterogeneity with branching evolutionary patterns.

AB - Plasma cell neoplasms are characterized by the proliferation of monoclonal plasma cells and include a spectrum of disorders with different clinical manifestations. Multiple myeloma (MM) is the second most common hematological malignancy and recent studies have indicated that almost all cases of MM are preceded by a precursor state of monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). The main clinical manifestations of MM are summarized by the CRAB symptoms: hypercalcemia, renal insufficiency, anemia, and bone lesions. Survival of multiple myeloma patients has significantly improved in the last two decades. The clinical benefit has occurred mainly in the younger population with the introduction of high-dose chemotherapy and autologous stem cell transplantation (ASCT) and with the use of novel agents at the time of relapse. The use of novel agents in the elderly population has also resulted in a significant benefit with respect to outcome. Despite the use of these new agents, and the improvement of the median survival from 3 to 6 years in the last 20 years, MM is generally considered an incurable disease and relapse occurs in virtually all patients. Cytogenetic analysis and molecular biology studies indicate that MM is a heterogeneous disease. The non-satisfactory cure rate has been conditioned by intraclonal heterogeneity with branching evolutionary patterns.

UR - http://www.scopus.com/inward/record.url?scp=85026512194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026512194&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-42370-8_2

DO - 10.1007/978-3-319-42370-8_2

M3 - Chapter

SN - 9783319423685

SP - 9

EP - 34

BT - Plasma Cell Neoplasms

PB - Springer International Publishing

ER -

Talamo G, Harcourt C, Zangari M. Clinical features, management, and therapy of plasma cell neoplasms: What pathologists need to know. In Plasma Cell Neoplasms: Pathogenesis, Diagnosis and Laboratory Evaluation. Springer International Publishing. 2016. p. 9-34 https://doi.org/10.1007/978-3-319-42370-8_2